The vaccine was 85% effective in preventing symptoms in volunteers 65 and older, the company said.
The numbers are not terribly different from data the company released in a statement Monday. As with Monday’s data, the company has released them via news release and not in a peer-reviewed report or as formal data for US Food and Drug Administration review.
“The primary analysis is consistent with our previously released interim analysis, and confirms that our COVID-19 vaccine is highly effective in adults, including those aged 65 years and over. We look forward to filing our regulatory…
